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Abstract 
  
Undesired drug release in acid medium from enteric microparticles has been widely 
reported. In this paper we investigate the relative contribution of microparticle and drug 
properties, specifically microsphere size and drug’s molecular weight and acid solubility, 
on the extent of such undesired release. A series of nine drugs with different 
physicochemical properties were successfully encapsulated into Eudragit S and Eudragit L 
microparticles using a novel emulsion solvent evaporation process. The process yielded 
spherical microparticles with a narrow size distribution (25-60 µm and 35-55 µm for 
Eudragit L and Eudragit S microparticles respectively). Upon incubation in acid medium 
(pH 1.2) for 2 h, the release of dipyridamole, cinnarizine, amprenavir, bendroflumethiazide, 
budenoside, prednisolone from both Eudragit microparticles was less than 10% of drug 
load and conformed with USP specification for enteric dosage forms. In contrast, more than 
10% of the entrapped paracetamol, salicylic acid and ketoprofen were released. Multiple 
regression revealed that the drug’s molecular weight was the most important factor that 
determined its extent of release in the acid medium, while its acid solubility and 
microsphere’s size had minor influences.  
 
Keywords: Microspheres, delayed release, enteric polymers, methacrylic polymers, gastric 
resistance, colonic delivery. 
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INTRODUCTION 
The last two decades witnessed the emergence of microencapsulation technology in 
pharmaceutical formulations1,2, which provided a unique platform for delayed and site-
specific oral drug delivery3. Modified release microparticles provide several advantages 
over conventional enteric and delayed release formulations such as larger surface area, 
potentially more uniform gastric emptying, and a more consistent drug release profile. 
Unfortunately, the particulate nature and large surface area are accompanied by a major 
challenge: the inhibition of drug release until the target site is reached. In in vitro  
dissolution tests, enteric formulations may release no more than 10% of their drug content 
during a two-hour incubation in 0.1N HCl, and subsequently should release more than 80% 
of their drug content within 45 min of changing the dissolution medium to intestinal 
conditions. While drug release in intestinal conditions is easily achieved given that readily 
suspended microparticles have a large surface area, minimising/inhibiting drug release in 
acidic conditions has proven challenging, and  insufficient control of drug release from 
microparticles in acid media has been reported4-10.  
 
It is commonly assumed that the microparticles’ surface area is the major factor influencing 
drug release from matrix microparticles11,12. This is in contrast to a previous report by our 
group which showed that reducing the size of Eudragit S microparticles by two thirds did 
not alter prednisolone release in the acidic medium13. Very little attention has been given to 
the chemical properties of the drug molecule itself. Silva and Ferreira7 used an empirical 
approach to explore the major factors affecting drug release from microparticles and 
suggested that high molecular weight and poor drug solubility in acid favours low drug 
release in acid medium. We have shown that the control of drug release was not necessarily 
influenced by drug distribution within the microparticle or by high drug solubility in acid14. 
Nevertheless, the relative importance of all these factors is still unclear.  
 
The aim of the work described in this paper was therefore to explore the relative 
importance of three drug and particle properties that have been directly related to drug 
release in gastric conditions6,7,15, namely, drug molecular weight and its solubility in acid, 
and microsphere size. Using an efficient o/o emulsion solvent evaporation method 
developed in our laboratory13,16, small uniform-size microparticles loaded with one of nine 
drug molecules of different physicochemical  properties were produced using two different 
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pH responsive polymers; Eudragit S and Eudragit L (pH thresholds 7.0 and 6.0 
respectively). In addition, multiple regression was used to investigate the relative 
importance of the 3 drug/microsphere properties and to explore the limitations of pH 
responsive matrix microparticles. 
 
MATERIALS AND METHODS  
Materials 
Paracetamol was supplied by Knoll AG (Ludwigshafen, Germany) and prednisolone was 
obtained from Sanofi-Aventis, (Romainville, France). Budenoside and amprenavir were 
gifts from Astra Zeneca (UK) and GlaxoSmithKline (UK) respectively. Ketoprofen, 
salicylic acid, dipyridamole, cinnarizine, bendroflumethiazide, sorbitan sesquioleate (Span 
83, Arlacel 83) and liquid paraffin were purchased from Sigma-Aldrich, (Poole, UK).  
Polymethacrylate polymers, Eudragit S and L, were generously provided by Evonik 
Degussa Chemicals (Darmstadt, Germany). 
Preparation of microparticles 
Drug loaded Eudragit S or Eudragit L microparticles were prepared as reported 
previously16. Briefly, 0.3 g of drug (indomethacin, paracetamol, salicylic acid, ketoprofen, 
naproxen, prednisolone, budenoside, bendroflumethiazide, amprenavir or dipyridamole) 
and 3 g of polymer (Eudragit S /L) were dissolved in 30 ml of absolute ethanol. The 
resulting solution was emulsified into 200 ml liquid paraffin containing sorbitan 
sesquioleate (Span 83) (1% w/w) as the emulsifier by stirring at a speed of 1000 rpm 
(Heidolph RZR1 stirrer, Heidolph Instruments, Schwabach, Germany) for 18 hours at room 
temperature. Solidified microparticles were collected by vacuum filtration, followed by 
washing three times using fresh batches of 50 ml n-hexane. Due to cinnarizine’s low 
solubility in ethanol, the drug and the polymer (Eudragit S or Eudragit L) were dissolved in 
30 ml of a mixture of ethanol: acetone (1:1 v/v) and microparticles were prepared as above. 
Microspheres size analysis 
The volume median diameter of each microparticle formulation suspended in 0.1N HCl 
was measured in triplicate using laser light scattering using a Malvern Mastersizer 2000 
with a 45mm lens (Malvern Instruments Ltd., Malvern, UK). Span of microsphere size was 
calculated as [D(v,0.9)−D(v, 0.1)] /D(v,0.5) where D(v,0.9), D(v,0.5) and D(v,0.1) are the 
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particle diameters at the 90th, 50th and 10th percentile respectively of the microsphere size 
distribution curve. Microsphere size analysis of each formulation was carried out in 
triplicate. 
 
X-Ray Powder Diffraction 
A Philips PW3710 Scanning X-Ray Diffractometer (Philips, Cambridge, UK) with a Cu Kα 
filter generated at 30mA and 45 kV was used to characterize the drug loaded 
microparticles. Samples were placed in a round disc sample holder and gently compressed 
and smoothed using Perspex block. Samples were scanned at 0.02 º/sec from 5º to 45º. The 
peak was calculated using X’Pert HighScore data analysis software (version 2.0a). 
 
Differential Scanning Calorimetry 
A DSC 7 Differential Scanning Calorimeter (PerkinElmer Instruments, Beaconsfields, UK) 
calibrated with indium, was used to assess the presence of crystalline drug in Eudragit S 
and Eudragit L microparticles. Microparticles (3-5 mg) were accurately weighed and 
placed in non-hermetic aluminum pan. Before starting the thermo scan, an isothermal 
period at 100 ºC (90˚C for ketoprofen microparticles) was applied for 5 min (to eliminate 
residual water content), then the samples were cooled and scanned from 50 ºC to 200 ºC at 
a rate of 10 ºC/min. Pyris Thermal Analysis Software was used to record and analyze the 
data. 
Drug encapsulation efficiency in microparticles 
Drug loaded microparticles (50 mg) were dissolved in 50ml methanol. The resulting 
solution was then diluted 10 times with HCl 0.1 N (for neutral and basic drugs) or with 
phosphate buffer pH 7.4 (for acidic drugs). Samples were filtered using a 0.22µm Millex 
filter and assayed spectrophotometrically. UV-Vis absorbance was measured using 
spectrophotometer at λmax = 243, 301, 254, 245, 246, 254, 263, and 280 nm for 
paracetamol, salicylic acid, ketoprofen, prednisolone, budenoside, bendroflumethiazide, 
amprenavir, and dipyridamole respectively. The encapsulation efficiency of cinnarizine was 
determined by dissolving 50 mg of microparticles in 50 ml methanol; 10 ml was taken and 
0.1M HCl was added to precipitate the polymers and made up to 100 ml. Samples were 
filtered through 0.22 µm Millex filters and 3.75 ml of the filtrate was added to 5 ml of 
acetonitrile followed by the addition of 1.25 ml of triphosphate buffer. Cinnarizine was 
assayed using Hypersil column Thermo Scientific (Runcorn, UK). A Hewlett-Packard 1050 
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series HPLC system (Agilent Technologies, UK) supplied with Waters 470 Millipore 
fluorescence detector (Milford, MA, USA) was utilized to detect samples.  The mobile 
phase, consisting of acetonitrile (70% v/v) and 10 mM potassium dihydrogen phosphate 
buffer (30% v/v), was eluted at a flow rate of 1 ml/min. The injection volume was 10 µl, 
and the fluorescence detector employed an excitation wavelength of 249 nm and emission 
wavelength of 311 nm.  
For each formulation, 3 different batches were assessed. Drug encapsulation efficiency was 
calculated as: 
 
100
clesmicropartiin  drug of mass ltheoretica
 clesmicropartiin  drug of mass measured
efficiencyion encapsulat ×=
 
 Eq.1 
Drug solubility in acidic medium 
In order to assess the influence of the drug’s solubility in acid on its release, the solubility 
of all encapsulated drugs in acidic medium were assayed. An excess amount of drug was 
added to 10 ml of HCl 0.1 N solution and shaken for 24 hours at 200 rpm and 37 °C. The 
saturated solutions were filtered (0.22 µm Milleux syringe filters), diluted as appropriate, 
and UV absorbance was measured at λmax as detailed in encapsulation efficiency section. 
Drug solubility was calculated from Beer-Lambert plots. In case of cinnarizine, drug 
concentration was assessed in saturated solution according to the HPLC method reported in 
the previous section. 
In vitro drug release from microparticles 
The USP II paddle apparatus (Model PTWS, Pharmatest, Hainburg, Germany) equipped 
with inline analysis coupled with 0.22 µm filter was employed to assess the microparticles’ 
dissolution profiles. Microparticles (0.1g) were accurately weighed and filled into capsule 
size 0. Each capsule was placed in a metal sinker to ensure a submerged position in a vessel 
containing 750 mL of 0.1N HCl as dissolution medium at 37 ± 0.5 °C. After 120 min, 250 
mL of 0.2M tri-sodium phosphate (equilibrated to 37 ± 0.5 °C) was added to the dissolution 
vessel, and the pH of the solution was adjusted to 7.4±0.05 if necessary using 5N HCl or 
4N NaOH solutions, and the dissolution experiment was continued for another 4 hours. 
Samples were taken every 5 min, the speed of the paddle was 100 rpm and each dissolution 
test was replicated 3 times. Data were processed using Icalis software (Icalis Data Systems 
Ltd, Berkshire, UK). A standard calibration curve was prepared for each drug in acidic and 
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buffer media. The absorbance of blank microparticles following the same dissolution 
procedure was measured and subtracted from those of the drug loaded microparticles to 
remove any interference from the Eudragit polymer and gelatin capsules. In case of 
cinnarizine, HPLC method reported above was applied to medium solutions. 
Multiple Regression 
Standard multiple regression using SPSS statistics software 17.0.0 (SPSS Inc., Chicago, 
U.S.) was conducted to assess the feasibility of predicting the control of drug release from 
microparticles in acidic medium from the following variables: drug molecular weight and 
its solubility in acid and microparticle diameter. The highly spherical morphology of the 
microparticles and the narrow size distribution of the majority of the prepared particles 
allowed the use of the square of diameter as representative of particles surface area. No 
violation of the assumptions of normality, linearity, multicolinearity and homoscedasticity 
was found. 
 
RESULTS AND DISCUSSION 
Microsphere properties 
All nine drugs were successfully encapsulated into Eudragit L and Eudragit S 
microparticles. The particles were spherical and had a uniform size distribution of 25-60 
µm and 35-55 µm for Eudragit L and Eudragit S respectively (Table 1). Representative 
SEM images of amprenavir and prednisolone loaded microparticles are shown in Fig.1. 
According to the SEM images, there was no evidence of porosity in any of the fabricated 
microparticles. In addition, X-ray powder diffraction and thermal analysis showed no 
evidence of crystallinity in the microparticles. 
 
Eudragit S microparticles were significantly larger than Eudragit L ones (paired samples t-
test, t(11)=3.39, p<0.01). A greater size of Eudragit S microparticles prepared under the 
same conditions as Eudragit L microparticles was also reported by Kendall et al. (2009) and 
was attributed to the nature of polymers; the higher viscosity of Eudragit S solution leading 
to the formation of larger emulsion droplets under the same stirring conditions. The 
encapsulation efficiency was high for all drugs (60-90%, Table 1) with Eudragit S 
microparticles having slightly (but statistically significantly) higher encapsulation 
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efficiencies than Eudragit L microparticles (paired samples t-test, t(11)=5.76, p<0.0005). 
The data shows the universal ability of this microparticle system to encapsulate drug 
molecules with a wide range of physicochemical properties.  
 
In vitro drug release from microparticles  
 
The release profiles of the nine drugs from Eudragit S and Eudragit L microparticles are 
shown in Figs. 2 and 3 respectively. Release of dipyridamole, cinnarizine, amprenavir, 
bendroflumethiazide, budenoside, prednisolone in acidic medium was well-controlled from 
both Eudragit S and Eudragit L microparticles, being less than 10% of the total drug 
content after 120 min. In contrast, the release of paracetamol, salicylic acid and ketoprofen 
were poorly controlled (>10% of drug content). 
 
Upon changing the pH to 6.8 and 7.4 for Eudragit L and Eudragit S microparticles 
respectively, rapid and complete drug release was achieved within 20 min and 45 min for 
Eudragit L and Eudragit S respectively for all drugs except for cinnarizine (Figs. 2 and 3). 
The slower release from Eudragit S microparticles could be due to its larger size (and hence 
smaller surface area), as well as a slower dissolution of the Eudragit S polymer. A lower 
dissolution rate of Eudragit S films (compared to Eudragit L ones) has been reported17. The 
limited release of cinnarizine at high pH is attributed to the poor solubility of the basic drug 
in phosphate buffer. It was noted that drug crystals appeared in the dissolution medium 
after pH change, indicating a rapid precipitation of cinnarizine.  
 
Influence of drug and particle properties on the control of drug release in acid 
medium  
Plots of drug release versus: i) drug molecular weight, ii) solubility in acidic medium and 
iii) microsphere size are shown in Figs. 4-6. No clear relationship was found between the 
solubility of the drug in acid medium or microsphere size and drug release in the acidic 
medium. In contrast, the drug’s molecular weight seemed to have a significant impact on its 
release, drug release decreasing exponentially with increasing molecular weight. A 
minimum molecular weight of around 300 Da seems to be necessary for control of drug 
release in acid medium (Fig. 6). A larger molecular size of the drug is likely to impede its 
movement through the polymeric network of the microparticle matrix and hence its release 
in acid medium 7. The relative importance of the two drug properties, molecular weight and 
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drug acid solubility, can be visualised in Figs. 7a-b. The figures clearly illustrate that 
release of larger drug molecules (>300 Da) are likely to be well-controlled and fulfil the 
USP criteria for delayed release formulations regardless of the drug’s solubility in the 
medium. 
 
To quantify the different influences, multi-linear regression was conducted, and yielded the 
following equation: 
  
Drug Released (%) =  
   55.123-0.123 MW+9.7 Log (Sol) -0.012 d2+ 1.55 P 
Eq.5  
where MW = drug molecular weight (Da), Log(Sol) = logarithm of drug saturation 
solubility in the acidic medium at 37 °C assessed in mg/L, d = Median diameter of 
microparticles (µm) and P is a constant relating to the polymer, P = 0 for Eudragit S and P 
= 1 for Eudragit L. 
 
It can be seen that drug release was increased by higher drug solubility and reduced by 
higher drug molecular weight and larger microparticle size. The multiple regression 
standardized coefficients revealed that molecular weight was by far the most prominent 
factor in controlling drug release (Standardized coefficient Beta = -0.617, p<0.001) while 
drug solubility (Beta = 0.403, p<0.01) and microsphere size (Beta = -0.396, p<0.05) had 
smaller influences. The model also suggests that the nature of polymethacrylate polymer 
(Eudragit S or Eudragit L) has no significant effect in controlling drug release in the acidic 
medium (Beta= 0.03, p=0.79). According to the model, replacing Eudragit S with Eudragit 
L was expected to increase drug release after two hours in the acid by less than 2%. 
Equation 5 was able to describe 84 % of the total variance (F (4, 17) = 22.111, p< 0.0005). 
Other factors not investigated in this study are also expected to affect drug release from 
polymeric matrix systems such as drug-polymer interactions18-21.  
  
CONCLUSIONS 
Nine drugs with different chemical natures were encapsulated in Eudragit L and Eudragit S 
microparticles using a novel emulsion solvent evaporation method. This showed the 
universality of the employed method for the preparation of delayed release particulate 
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formulations. The particles had the desirable properties of spherical morphology, smooth 
surface, small microsphere size (<100µm) and a uniform size distribution. However, all the 
drug-loaded microparticles did not conform to USP specifications with respect to control of 
drug release in acid medium for delayed release preparations i.e. release of <10% of drug 
content following a 2 hour incubation in an acid medium. Paracetamol, ketoprofen and 
salicylic acid were released at >10%. When the influences of the drug’s molecular weight, 
acid solubility and microsphere size on drug release in acid medium were modelled using 
multiple regression, the drug molecular weight was found to be the most important 
predictor while the drug’s acid solubility and the microsphere size were less influential.  
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Fig. 1. SEM micrograph of amprenavir (1a and 1b), prednisolone (1c and 1d) loaded 
Eudragit S and Eudragit L microparticles 
 
Fig. 2. % drug release from Eudragit L microparticles with time, using a pH-change 
dissolution method. 
 
Fig. 3. % drug release from Eudragit S microparticles with time, using a pH-change 
dissolution method. 
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 13 
Fig. 4. % drug release from microparticles as a function of drug acid solubility (the dotted 
line represents USP criteria) 
 
Fig. 5. % drug release from microparticles as a function of microsphere size (the dotted line 
represents USP criteria) 
 
Fig. 6. % drug release from microparticles as a function of drug molecular weight (the 
dotted line represents USP criteria) 
 
Fig. 7. Relative importance of drug molecular weight and drug acid solubility on drug 
release from (a) Eudragit S and (b) Eudragit L microparticles after 2 hours in gastric 
medium (sphere size is proportional to drug molecular weight, the dotted line represents 
USP criteria).  
 
List of tables  
Table 1: Drug’s molecular weight and microsphere size, encapsulation efficiency and 
percentage drug release in acid medium from Eudragit S and Eudragit L microparticles. 
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Table 1 
Particle size 
D(0,5)±SD µm (Span ±S.D)  
Encapsulation efficiency 
(%) ±SD 
Drug release after 2hours 
(%)±SD 
Drug 
Solubility 
in acidic 
medium 
(mg/L) 
Molecular 
weight 
(Da) Eudragit S Eudragit L Eudragit S Eudragit L Eudragit S Eudragit L 
Salicylic acid 1,435.5 138.1 46  ± 4.2 (3.0 ± 4.0) 31 ± 1.3 (0.7 ± 0.0) 107.2 ± 5.1 104 ± 1. 9 40.8 ± 0.5 86.9 ± 1.3 
Paracetamol 12,309 151.1 38 ± 1.9 (0.8 ± 0.07) 30 ± 1.2 (1.2 ± 0.1) 83.5 ± 0.7 83 ± 1.0 57.3 ± 0.3 63.2 ± 0.4 
Ketoprofen 75.6 254.2 36 ± 1.2 (0.9 ± 0.3) 28 ± 0.9 (0.9 ± 0.1) 91.1 ± 1.1 90 ± 0.9 6.9 ± 0.8 17.1 ± 2.9 
Prednisolone 218 360.4 48 ± 1.6 (0.6 ± 0.4) 38 ± 0.5 (0.7 ± 0.2) 80 ± 3.2 77 ± 1.2 1.6 ± 0.3 7.1 ± 0.3 
Cinnarizine 2,110.6 369.5 49 ± 2.4 (0.7 ± 0.1) 56 ± 6.8 (1.2 ± 0.3) 64 ± 2.7 62 ± 1.9 0.0 ± 0.0 1.5 ± 0.2 
Bendroflumethiazide 30.2 421.4 46 ± 13.5 (1.0 ± 0.1) 41 ± 4.1 (1.0 ± 0.1) 68 ± 0.9 63 ± 1.0 1.6 ± 0.3 3.1 ± 0.1 
Budenoside 20.0 430.5 44 ± 1.6 (1.0 ± 0.2) 33 ± 0.5 (0.7 ± 0.1) 59 ± 5.7 53 ± 1.6 1.7 ± 0.8 3.4 ± 0.0 
Dipyridamole 29,200 504.7 56 ± 0.2 (0.8 ± 0.1) 60 ± 5.9 (0.9 ± 0.1) 75 ± 1.7 70 ± 0.8 0.5 ± 0.4 0.0 ± 0.0 
Amprenavir 89.0 505.6 36 ± 0.2 (0.9 ± 0.1) 27 ± 1.1 (0.9 ± 0.2) 68 ± 3.1 60 ± 0.8 0.0 ± 0.0 0.0 ± 0.0 
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Figure 1a  
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Figure 1b  
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Figure 1c  
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Figure 1d  
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% drug release from Eudragit L microparticles with time, using a pH-change dissolution method  
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% drug release from Eudragit S microparticles with time, using a pH-change dissolution method  
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% drug release from microparticles as a function of drug acid solubility (the dotted line represents 
USP criteria)  
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% drug release from microparticles as a function of microsphere size (the dotted line represents 
USP criteria)  
220x143mm (96 x 96 DPI)  
 
Page 22 of 25
John Wiley & Sons, Inc.
Journal of Pharmaceutical Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
  
 
 
% drug release from microparticles as a function of drug molecular weight (the dotted line 
represents USP criteria)  
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Relative importance of drug molecular weight and drug acid solubility on drug release from (a) 
Eudragit S and (b) Eudragit L microparticles after 2 hours in gastric medium (sphere size is 
proportional to drug molecular weight, the dotted line represents USP criteria)  
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Relative importance of drug molecular weight and drug acid solubility on drug release from (a) 
Eudragit S and (b) Eudragit L microparticles after 2 hours in gastric medium (sphere size is 
proportional to drug molecular weight, the dotted line represents USP criteria).  
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